Agendia, Inc.

135 articles with Agendia, Inc.

• Agendia and Paige Announce Landmark Strategic Partnership to Revolutionize Treatment Planning in Breast Cancer

  11/18/2020

  Co-development program will utilize next-generation digital pathology platform and AI-based technology to provide real-time genomic testing results

• Agendia to Showcase Robust Clinical Research at SABCS 2020 Emphasizing Need for Diversity of Data to Treat Breast Cancer Patients

  11/17/2020

  Agendia, Inc., a world leader in precision oncology for breast cancer, announced today that it will present new data from ongoing clinical research evaluating the MammaPrint ® and BluePrint ® genomic tests at the upcoming 2020 San Antonio Breast Cancer

• Agendia Presents Robust and Accurate Next Generation Sequencing Results at the Association for Molecular Pathology 2020 Annual Meeting & Expo

  11/17/2020

  Agendia, Inc., a world leader in precision oncology for breast cancer, today announced a poster presentation at the Association for Molecular Pathology (AMP) 2020 Annual Meeting & Expo.

• Agendia to Participate in Piper Sandler 32nd Annual Virtual Healthcare Conference

  11/16/2020

  Agendia, Inc., a world leader in precision oncology for breast cancer, today announced its participation in the Piper Sandler 32nd Annual Virtual Healthcare Conference, which takes place November 30 – December 3, 2020.

• Agendia to Participate in 2020 Canaccord Genuity Virtual MedTech & Diagnostics Forum

  11/5/2020

  Agendia, Inc ., a world leader in precision oncology for breast cancer, today announced its participation in the 2020 Canaccord Genuity Virtual MedTech & Diagnostics Forum, which takes place November 19, 2020 . Agendia Chief Executive Mark Straley will present on Thursday, November 19 at 9:00 am ET , and will be accompan

• Agendia Co-Founder Named to Eighth Annual OncLive® Giants of Cancer Care® Class of Inductees

  10/28/2020

  Laura van 't Veer among 15 trailblazers in oncology honored at the 2020 virtual awards ceremony

• MammaPrint® Approved for Reimbursement in Germany

  10/21/2020

  Agendia Inc., a world leader in precision oncology for breast cancer, announced that the Federal Joint Committee has approved MammaPrint®, Agendia's 70-Gene Breast Cancer Recurrence Assay.

• Agendia, HiSS Diagnostics and PathoNext offer local MammaPrint and BluePrint testing for breast cancer patients in Germany

  10/6/2020

  Agendia Inc., a world leader in precision oncology for breast cancer, announced the availability of local testing for its CE-marked MammaPrint® BluePrint® Breast Cancer Recurrence and Molecular Subtyping tests, provided by PathoNext lab in Leipzig, Germany.

• Agendia Presents New Data Demonstrating Clinical Utility for MammaPrint and BluePrint at the 2020 European Breast Cancer Conference Virtual Event

  10/2/2020

  Presentations to include follow-up MINDACT study data and evaluations on the use of MammaPrint to guide treatment decisions in lobular cancers and for screen-detected breast cancers versus interval-detected breast cancers IRVINE, Calif. , Oct. 2, 2020 /PRNewswire/ -- Agendia, Inc., a world leader in precision oncology for breast cancer, today announced the presentation o

• Agendia Celebrates Breast Cancer Awareness Month with Digital Art Installation

  10/1/2020

  In celebration of Breast Cancer Awareness Month, Agendia, Inc ., a world leader in precision oncology for breast cancer, is proud to present the I AM HERE campaign, a collection of illustrations and stories that capture the incredibly personal journey of a breast canc

• Agendia Presents New Data Demonstrating MammaPrint's Clinical Utility in Treatment Decisions for Ultra-Low Risk Breast Cancer Patients at the European Society for Medical Oncology Virtual Congress

  9/17/2020

  Agendia, Inc., a world leader in precision oncology for breast cancer, presented data at the European Society for Medical Oncology Virtual Congress 2020 showing that MammaPrint's Ultra-Low risk threshold can identify postmenopausal breast cancer patients who will have an excellent prognosis with limited or no tamoxifen treatment.

• MINDACT Study Shows MammaPrint® Provides Widespread Health System Cost Savings

  8/25/2020

  Use of MammaPrint genetic assay alongside clinical assessment is cost-effective versus clinical assessment alone

• Agendia Expands Management Team to Meet Company Momentum, Appoints Brian Dow as Chief Financial Officer

  7/29/2020

  Chief Operating Officer Kurt Becker to Take on Broadened Role Overseeing Global Operations and Research and Development

• Agendia Publishes Unprecedented Full Genome Dataset from MINDACT Trial for the Advancement of Translational Research in Communications Biology

  7/27/2020

  Agendia, Inc., a world leader in precision oncology for breast cancer, announced the publication of MINDACT trial data in the July 27 issue of Communications Biology, a Nature Publishers Journal.

• Long-Term Follow Up Data from Groundbreaking MINDACT Study Continues to Demonstrate Clinical Utility of MammaPrint™

  5/29/2020

  Agendia, Inc., a world leader in precision oncology for breast cancer, announced new data from MINDACT, the prospective randomized trial designed to further demonstrate the clinical utility of MammaPrint® risk scoring when determining a breast cancer patient's need for chemotherapy.

• Agendia Announces Data Presented at ASCO 2020 Demonstrating Importance of Further Classification of Breast Cancers to Enable Precise Prognosis and Treatment

  5/29/2020

  Presentations outline how BluePrint® genomic testing enables further categorization of HER2-positive cancer and reclassification of ER+ tumors for patients' benefit FLEX registry reinforces the clinical and real-world utility of MammaPrint® and BluePrint to improve stratification of breast cancer patients   [29-May-2020]   IRVINE, Calif. and AMSTERDAM , May 29,

• Agendia to Showcase New Data at ASCO 2020 That Further Stratifies Breast Cancer Patients for More Precise Therapy Recommendations

  5/14/2020

  Agendia, Inc., a world leader in precision oncology for breast cancer, announced today that they will present new data from its ongoing clinical research evaluating the MammaPrint® and BluePrint® genomic tests at the upcoming American Society of Clinical Oncology Annual Meeting (ASCO), taking place virtually May 29-May 31, 2020.

• Agendia Co-Founder and Chief Scientific Officer René Bernards, PhD Elected to the National Academy of Sciences

  5/7/2020

  Development of MammaPrint®, first FDA-cleared molecular diagnostic test for personalized treatment of breast cancer, considered a landmark achievement in breast cancer testing and treatment

• Agendia Appoints Two Industry Veterans to Board of Directors

  5/31/2019

  Agendia, Inc., a world leader in precision oncology, announced today the appointment of industry veterans Laurie Heilmann and François Ferré, Ph.D. to its board of directors.

• Agendia Announces Creation of New Center of Innovation and R&D Excellence

  4/17/2019

  Simultaneous creation of Global Lab Center of Excellence